SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing presentation: reset
Mutation-driven drug development (targeted agents) vs. immunotherapeutics development
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
1 of
1
|
Mutation-driven drug development (targeted agents) vs. immunotherapeutics development
Alexander M Eggermont
Gustave Roussy Cancer Institute, Villejuif, Paris-Sud, France
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
1 of
1
|
